PDP Pediapharm

December 26, 2013 - Pediapharm Inc. (TSX VENTURE:PDP) ("Pediapharm") is pleased
to announce that it has successfully met the necessary requirements to begin
trading on the TSX Venture Exchange. The common shares of Pediapharm will begin
trading on December 27, 2013, at market open under the ticker symbol "PDP". In
connection with the listing on the TSX Venture Exchange, on December 10, 2013,
Pediapharm announced it had received gross proceeds of $6,967,490 from its
equity financing activities.


"The entire board of Pediapharm views the listing of TSX Venture as a strong
signal about the capabilities of the team and the robustness of the business
model. The Company will now have the financial means to substantially accelerate
its growth by continuing to build its product pipeline through licensing and
acquisition. This is excellent news for Canadian children as they will now have
access to a greater number of innovative therapies" said Pierre Lapalme,
Chairman of Pediapharm.


Sylvain Chretien, President and CEO of Pediapharm commented: "The Pediapharm
team is highly motivated to execute its business plan with the ultimate
objective of creating value for the shareholders of Pediapharm." 


Additional information can be found in at www.pedia-pharm.com and at www.sedar.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


This press release shall not constitute an offer to sell or the solicitation of
an offer to buy any securities, nor shall there be any sale of securities in any
state in the United States in which such offer, solicitation or sale would be
unlawful. The securities referred to herein have not been and will not be
registered under the United States Securities Act of 1933, as amended, and may
not be offered or sold in the United States absent registration or an applicable
exemption from registration requirements.


About Pediapharm

Pediapharm is the only Canadian specialty pharmaceutical company, dedicated to
serving the needs of the pediatric community. Its mission is to bring to the
Canadian market the latest innovative pediatric products with the objective to
improve the health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements with partners
from Canada and other countries around the world. The company's innovative
product portfolio includes NYDA(R); a breakthrough treatment for head lice and
its eggs; EpiCeram(R) a non-steroid emulsion for eczema; KoolEffect(TM) which
reduces the symptoms of fever; and VapoLyptus(TM); a soothing vapour patch of
eucalyptus and camphor. 


Caution concerning forward-looking statements 

This news release contains forward-looking statements that involve risks and
uncertainties. Forward-looking statements or information are based on current
expectations, estimates and projections that involve a number of risks and
uncertainties which could cause actual results to differ materially from those
anticipated by Pediapharm Inc. The forward-looking statements or information
contained in this news release are made as of the date hereof and Pediapharm
Inc. does not undertake any obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new
information, future events or otherwise, unless so required by applicable
securities laws.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pediapharm Inc.
Sylvain Chretien
President, CEO
514-762-2026 ext. 201
sylvain.chretien@pedia-pharm.com


Pediapharm Inc.
Roland Boivin
CFO
514-762-2026 ext. 202
roland.boivin@pedia-pharm.com

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024